Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia
Seroprevalence
Pandemic
DOI:
10.1016/j.jiph.2021.04.006
Publication Date:
2021-04-24T15:38:23Z
AUTHORS (19)
ABSTRACT
Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for better evaluation virus spread and monitoring progress COVID-19 pandemic in population. In Kingdom Saudi Arabia (KSA), SARS-CoV-2 has been reported specific regions, but an extensive nationwide study not reported. Here, we report to determine prevalence population KSA during pandemic, using serum samples from healthy blood donors, non-COVID patients healthcare workers (HCWs) six different regions kingdom, with addition patients. A total 11,703 were collected including; 5395 residual donors (D); 5877 through sera at clinical biochemistry labs (P); 400 consented HCWs. To SARS-CoV-2, all samples, positive control RT-PCR confirmed patients, subjected in-house ELISA sample pooling strategy, which was further validated testing individual that make up some pools, statistical estimation method estimates. Overall (combining D P groups) estimate around 11% Arabia; 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), 18.8% Makkah. Makkah only group had rate 24.4% 12.8% cities Jeddah, respectively. The across sampled areas would be 12 times infection rate. Among HCWs, 7.5% (4.95–10.16 CI 95%) reactive antibodies without reporting any previously infection. This higher HCWs hypertension. also presents demographics co-morbidities subset non-COVID-19 Our estimates overall national serological 11%, apparent disparity between regions. indicates asymptomatic or mild unreported cases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (25)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....